Dr. Jonathan Canaani is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and the director of the Hematologic Malignancies Program at NewYork-Presbyterian Brooklyn Methodist Hospital. Dr. Canaani received his B.S. with honors from the University of Tel-Aviv, Israel in 2003, and his M.D. from the Tel-Aviv University School of Medicine in 2009. He trained in Internal Medicine at the Tel-Aviv Medical Center. During residency, Dr. Canaani also completed a research fellowship at the Weizmann Institute of Science focusing on the molecular biology of hematopoietic stem cells. He continued his medical training at the Hospital of the University of Pennsylvania, completing a fellowship in Hematology and Medical Oncology in 2013. During his fellowship at Penn, Dr. Canaani focused his clinical efforts within the field of leukemia and became involved in studying response patterns to novel FLT3 inhibitors in acute myeloid leukemia patients. During fellowship, Dr. Canaani was awarded the American Society of Hematology (ASH) Research Training Award for Fellows (ASH RTAF). In 2016, Dr. Canaani relocated to Israel to serve as Director of the Adult Leukemia Program at the Sheba Medical Center where he also held the title of Senior Lecturer of Hematology at the University of Tel-Aviv. His main area of research has been focused on conducting translational research in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), which aims to delineate molecular correlates that are associated with specific response patterns in leukemia patients receiving conventional chemotherapies and  novel targeted therapies. In collaboration with the European Society for Blood and Marrow Transplantation (EBMT), Dr. Canaani made several important contributions to clinical research outlining the clinical outcomes of AML and ALL patients undergoing allogeneic stem cell transplantation. With the recent introduction of novel immune and signaling transduction-based therapeutic platforms into the routine care of leukemia patients, Dr. Canaani's current research efforts endeavor to integrate precision oncology approaches to evaluate real-world outcomes of designated patient subsets and to improve cancer care delivery.